Abstract
The objective of this work was the application of peptidomics®1 technologies for the detection and identification of reliable and robust biomarkers for Alzheimers disease (AD) contributing to facilitate and further improve the diagnosis of AD. Using a new method for the comprehensive and comparative profiling of peptides, the differential peptide display® (DPD), 312 cerebrospinal fluid (CSF) samples from AD patients, cognitively unimpaired subjects and from patients suffering from other primary dementia disorders were analysed as four independent analytical sets. By combination with a cross validation procedure, candidates were selected from a total of more than 6,000 different peptide signals based on their discriminating power. Twelve candidates were identified using mass-spectrometric techniques as fragments of the possibly neuroprotective neuroendocrine protein VGF and another one as the complement factor C3 descendent C3f. The combination of peptide profiling and cross validation resulted in the detection of novel potential biomarkers with remarkable robustness and a close relation to AD pathophysiology.
Keywords: Alzheimer's disease, biological marker, cerebrospinal fluid proteins, differential peptide display, neuropeptides, peptides, peptidomics, proteomics
Combinatorial Chemistry & High Throughput Screening
Title: Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease
Volume: 8 Issue: 8
Author(s): Hartmut Selle, Jens Lamerz, Katharina Buerger, Andreas Dessauer, Klaus Hager, Harald Hampel, Johann Karl, Markus Kellmann, Lars Lannfelt, Jukka Louhija, Matthias Riepe, Wolfgang Rollinger, Hayrettin Tumani, Michael Schrader and Hans-Dieter Zucht
Affiliation:
Keywords: Alzheimer's disease, biological marker, cerebrospinal fluid proteins, differential peptide display, neuropeptides, peptides, peptidomics, proteomics
Abstract: The objective of this work was the application of peptidomics®1 technologies for the detection and identification of reliable and robust biomarkers for Alzheimers disease (AD) contributing to facilitate and further improve the diagnosis of AD. Using a new method for the comprehensive and comparative profiling of peptides, the differential peptide display® (DPD), 312 cerebrospinal fluid (CSF) samples from AD patients, cognitively unimpaired subjects and from patients suffering from other primary dementia disorders were analysed as four independent analytical sets. By combination with a cross validation procedure, candidates were selected from a total of more than 6,000 different peptide signals based on their discriminating power. Twelve candidates were identified using mass-spectrometric techniques as fragments of the possibly neuroprotective neuroendocrine protein VGF and another one as the complement factor C3 descendent C3f. The combination of peptide profiling and cross validation resulted in the detection of novel potential biomarkers with remarkable robustness and a close relation to AD pathophysiology.
Export Options
About this article
Cite this article as:
Selle Hartmut, Lamerz Jens, Buerger Katharina, Dessauer Andreas, Hager Klaus, Hampel Harald, Karl Johann, Kellmann Markus, Lannfelt Lars, Louhija Jukka, Riepe Matthias, Rollinger Wolfgang, Tumani Hayrettin, Schrader Michael and Zucht Hans-Dieter, Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease, Combinatorial Chemistry & High Throughput Screening 2005; 8 (8) . https://dx.doi.org/10.2174/138620705774962391
DOI https://dx.doi.org/10.2174/138620705774962391 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Current Pharmaceutical Design Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders
Current Psychiatry Reviews Acetylcholinesterase Inhibition in Alzheimers Disease
Current Pharmaceutical Design New Perspectives of Alzheimer Disease Diagnosis – the Most Popular and Future Methods
Medicinal Chemistry Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Current Alzheimer Research Mitochondrial Biology and Neurological Diseases
Current Neuropharmacology Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Subject Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Current Topics in Medicinal Chemistry Nicotinic Acetylcholine Receptors as Drug Targets
Current Drug Targets - CNS & Neurological Disorders DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets